The History of Live Attenuated Centrin Gene-Deleted Leishmania Vaccine Candidates

被引:23
作者
Volpedo, Greta [1 ,2 ]
Bhattacharya, Parna [3 ]
Gannavaram, Sreenivas [3 ]
Pacheco-Fernandez, Thalia [1 ,2 ]
Oljuskin, Timur [3 ]
Dey, Ranadhir [3 ]
Satoskar, Abhay R. [1 ,2 ]
Nakhasi, Hira L. [3 ]
机构
[1] Ohio State Univ, Dept Pathol, Wexner Med Ctr, Columbus, OH 43201 USA
[2] Ohio State Univ, Dept Microbiol, Wexner Med Ctr, Columbus, OH 43201 USA
[3] US FDA, Div Emerging & Transfus Transmitted Dis, Ctr Biol Evaluat & Res, Silver Spring, MD 20993 USA
关键词
Leishmania; visceral leishmaniasis; vaccine; live attenuated parasite vaccines; pan-Leishmania vaccine; WORLD CUTANEOUS LEISHMANIASIS; CANINE VISCERAL LEISHMANIASIS; PROTEINASE-DEFICIENT MUTANTS; SUSCEPTIBLE BALB/C MICE; RISK CHILD POPULATION; P36(LACK) DNA VACCINE; CD4(+) T-CELLS; IMMUNE-RESPONSE; FIELD TRIAL; PROTECTIVE IMMUNITY;
D O I
10.3390/pathogens11040431
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Leishmaniasis, caused by an infection of the Leishmania protozoa, is a neglected tropical disease and a major health problem in tropical and subtropical regions of the world, with approximately 350 million people worldwide at risk and 2 million new cases occurring annually. Current treatments for leishmaniasis are not highly efficacious and are associated with high costs, especially in low- and middle-income endemic countries, and high toxicity. Due to a surge in the incidence of leishmaniases worldwide, the development of new strategies such as a prophylactic vaccine has become a high priority. However, the ability of Leishmania to undermine immune recognition has limited our efforts to design safe and efficacious vaccines against leishmaniasis. Numerous antileishmanial vaccine preparations based on DNA, subunit, and heat-killed parasites with or without adjuvants have been tried in several animal models but very few have progressed beyond the experimental stage. However, it is known that people who recover from Leishmania infection can be protected lifelong against future infection, suggesting that a successful vaccine requires a controlled infection to develop immunologic memory and subsequent long-term immunity. Live attenuated Leishmania parasites that are non-pathogenic and provide a complete range of antigens similarly to their wild-type counterparts could evoke such memory and, thus, would be effective vaccine candidates. Our laboratory has developed several live attenuated Leishmania vaccines by targeted centrin gene disruptions either by homologous recombination or, more recently, by using genome editing technologies involving CRISPR-Cas9. In this review, we focused on the sequential history of centrin gene-deleted Leishmania vaccine development, along with the characterization of its safety and efficacy. Further, we discussed other major considerations regarding the transition of dermotropic live attenuated centrin gene-deleted parasites from the laboratory to human clinical trials.
引用
收藏
页数:16
相关论文
共 131 条
[1]   A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L-major [J].
Ahmed, SB ;
Bahloul, C ;
Robbana, C ;
Askri, S ;
Dellagi, K .
VACCINE, 2004, 22 (13-14) :1631-1639
[2]  
Alexander J, 1998, J IMMUNOL, V161, P6794
[4]   Case study for a vaccine against leishmaniasis [J].
Alvar, Jorge ;
Croft, Simon L. ;
Kaye, Paul ;
Khamesipour, Ali ;
Sundar, Shyam ;
Reed, Steven G. .
VACCINE, 2013, 31 :B244-B249
[5]   Leishmaniasis Worldwide and Global Estimates of Its Incidence [J].
Alvar, Jorge ;
Velez, Ivan D. ;
Bern, Caryn ;
Herrero, Merce ;
Desjeux, Philippe ;
Cano, Jorge ;
Jannin, Jean ;
den Boer, Margriet .
PLOS ONE, 2012, 7 (05)
[6]   Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease [J].
Amaral, VF ;
Teva, A ;
Oliveira-Neto, MP ;
Silva, AJ ;
Pereira, MS ;
Cupolillo, E ;
Porrozzi, R ;
Coutinho, SG ;
Pirmez, C ;
Beverley, SM ;
Grimaldi, G .
MEMORIAS DO INSTITUTO OSWALDO CRUZ, 2002, 97 (07) :1041-1048
[7]   Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: Safety, immunogenicity, and efficacy during the first 12 months of follow-up [J].
Armijos, RX ;
Weigel, MM ;
Aviles, H ;
Maldonado, R ;
Racines, J .
JOURNAL OF INFECTIOUS DISEASES, 1998, 177 (05) :1352-1357
[8]   Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis [J].
Armijos, RX ;
Weigel, MM ;
Calvopina, M ;
Hidalgo, A ;
Cevallos, W ;
Correa, J .
VACCINE, 2004, 22 (9-10) :1320-1326
[9]   Field trial of a vaccine against new world cutaneous leishmaniasis in an at-risk child population: How long does protection last? [J].
Armijos, RX ;
Weigel, MM ;
Romero, L ;
Garcia, V ;
Salazar, J .
JOURNAL OF INFECTIOUS DISEASES, 2003, 187 (12) :1959-1961
[10]   Characterization of a new Leishmania major strain for use in a controlled human infection model [J].
Ashwin, Helen ;
Sadlova, Jovana ;
Vojtkova, Barbora ;
Becvar, Tomas ;
Lypaczewski, Patrick ;
Schwartz, Eli ;
Greensted, Elizabeth ;
Van Bocxlaer, Katrien ;
Pasin, Marion ;
Lipinski, Kai S. ;
Parkash, Vivak ;
Matlashewski, Greg ;
Layton, Alison M. ;
Lacey, Charles J. ;
Jaffe, Charles L. ;
Volf, Petr ;
Kaye, Paul M. .
NATURE COMMUNICATIONS, 2021, 12 (01)